HCG as TRT Adjuvant: Intratesticular Testosterone and Fertility Preservation
HCG as a TRT adjuvant: how low-dose hCG preserves intratesticular testosterone and fertility under exogenous testosterone therapy. Coviello, Panken 2025.
Testosterone replacement therapy (TRT) presents researchers and clinicians with a paradox: the treatment that normalises serum testosterone also shuts down the very axis that keeps the testes functional. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, collapses intratesticular testosterone to a fraction of its physiological level, and gradually eliminates spermatogenesis. For men who need androgen support but also want to preserve fertility, human chorionic gonadotropin (hCG) has become the standard bridge between these two goals. The 2024 and 2025 literature has refined this picture considerably, most notably through Panken and colleagues' dose-independence finding.
Reproductive hormone that mimics luteinizing hormone (LH) activity. Used in research on testosterone production, fertility, and hormonal regulation. Available in 6,000 IU and 15,000 IU vials.
The Problem: HPG-Axis Suppression under TRT
Normal testicular function depends on pulsatile GnRH release from the hypothalamus, which drives pituitary LH and FSH secretion. LH binds the LH/CG receptor on Leydig cells and maintains intratesticular testosterone (ITT) at concentrations roughly 100-fold higher than in serum. This extraordinarily high local concentration is not a laboratory curiosity: it is required for spermatogenesis. FSH acts complementarily on Sertoli cells.
When exogenous testosterone is administered, the negative feedback loop on the hypothalamus and pituitary silences GnRH pulsing. LH and FSH fall to negligible levels, Leydig cells lose their trophic signal, and ITT collapses. Testicular volume decreases measurably within weeks, and sperm production declines toward azoospermia. This is reversible in many men after cessation, but the recovery timeline is unpredictable and not universal, particularly after prolonged or high-dose use.
The practical consequence is that serum testosterone normalisation on TRT does not translate to testicular preservation. A patient on standard TRT can have perfectly normal blood levels and near-zero ITT at the same time.
hCG Mechanism: LH Mimicry at the Leydig Cell
hCG and LH share the same receptor (LHCGR), a G protein-coupled receptor expressed on Leydig cells. Binding activates adenylyl cyclase through Gs, raising cAMP, activating PKA, mobilising cholesterol via StAR into the mitochondria, and initiating the steroidogenic cascade that ends in testosterone. hCG and LH also engage ERK1/2 and PI3K/AKT signalling.
The pharmacologically decisive difference between the two is half-life. LH has a serum half-life of roughly 20 minutes, while hCG, thanks to the C-terminal peptide extension on its beta subunit with four O-linked oligosaccharides, has a terminal half-life of 24 to 36 hours. A single hCG injection therefore produces a sustained LH-like stimulus, allowing two- or three-times-weekly dosing regimens rather than the pulsatile pattern of native LH.
From the Leydig cell's perspective, hCG is essentially a long-acting LH agonist. When given alongside exogenous testosterone, hCG bypasses the suppressed pituitary and directly maintains steroidogenesis, rescuing ITT even when endogenous LH is zero.
The Foundational Study: Coviello Low-Dose hCG under TRT
The study that established the modern use of low-dose hCG as a TRT adjuvant is Coviello and colleagues' trial in the Journal of Clinical Endocrinology & Metabolism. The design was rigorous: healthy men received exogenous testosterone sufficient to suppress gonadotropins, with one group receiving concurrent hCG at low doses and others receiving testosterone alone. Intratesticular testosterone was measured directly by testicular fluid aspiration, not inferred from serum.
The key observation was a dose-response relationship between hCG and ITT preservation. Doses as low as 125 IU to 250 IU every other day preserved ITT at substantial fractions of the baseline physiological level, while testosterone-only controls showed profound ITT suppression. The clinical implication was immediate: adding a modest dose of hCG to TRT restores the hormonal environment required for ongoing spermatogenesis, without the supra-physiological serum testosterone that higher hCG doses can produce.
Coviello et al. JCEM - Foundational hCG/TRT Study
Coviello and colleagues demonstrated by direct intratesticular testosterone measurement that low-dose hCG (on the order of 125-500 IU every other day) restores ITT in men rendered hypogonadotropic by exogenous testosterone. The study provided the pharmacological rationale for the now-standard addition of low-dose hCG to testosterone replacement regimens when fertility or testicular volume preservation is a goal.
2025 Update: Panken F&S Reports - Dose Independence
The most important recent data point on hCG dosing comes from Panken and colleagues' 2025 paper in F&S Reports. The cohort was men recovering spermatogenesis after non-prescribed androgen use, and the question was whether higher hCG doses produced faster or larger recovery of total motile sperm count (TMSC).
The answer was striking: hCG dose had no measurable effect on TMSC increase. The regression coefficient for dose was 0.011 with P = 0.21, well outside statistical significance. In plain terms, pushing hCG beyond the low-dose range did not speed recovery or enlarge the final sperm count.
Panken et al. 2025 F&S Reports - Low-Dose Is Enough
In a cohort of men restoring fertility after non-prescribed androgen exposure, hCG dose had no significant effect on total motile sperm count increase (coefficient 0.011, P = 0.21). Higher doses did not accelerate or enhance recovery. The practical implication is that low-dose hCG regimens achieve the same outcome as higher-dose protocols, with less cost, less side-effect burden, and a cleaner serum-testosterone profile.
This reframes the older debate. If the only endpoint were ITT as measured by Coviello, one might still argue for titration. But once sperm output is the endpoint, the dose-response curve flattens. The takeaway for TRT-adjuvant use is that there is no compelling reason to push hCG above the low-dose window established by Coviello.
Post-Cycle and Post-TRT: Shoaib 2025 + Muir 2025 Meta-Analysis
Two 2025 reviews consolidate the evidence base for hCG in spermatogenesis induction and recovery.
Shoaib and colleagues (Cureus 2025, PMC12590188) published a systematic review of hCG for male infertility. The regimens that reliably induced spermatogenesis in hypogonadotropic patients clustered around 1500 to 3000 IU two to three times per week. Recovery timelines varied from a few months to two years, with the broadest predictive factors being baseline testicular volume and the duration of prior suppression.
Muir and colleagues (Clinical Endocrinology 2025;102:167-177, PMID 39445789) performed a broader meta-analysis of gonadotropin therapy for spermatogenesis induction in hypogonadotropic hypogonadism. The overall finding was that hCG, with or without FSH, reliably induces spermatogenesis in the majority of patients, with response rates dependent on duration of treatment and baseline fertility status.
Shoaib 2025 + Muir 2025 - Spermatogenesis Induction
Shoaib et al. (Cureus 2025, PMC12590188) and Muir et al. (Clin Endocrinol 2025;102:167-177, PMID 39445789) together establish hCG, typically 1500-3000 IU two or three times per week, as the evidence-backed approach for spermatogenesis induction and post-TRT recovery. Meta-analytic response rates are high in hypogonadotropic patients, with duration of suppression and baseline testicular volume as the main predictors of recovery kinetics.
hCG Monotherapy vs. Combination with FSH
Whether to add FSH to hCG is one of the recurring questions in fertility research. The 2024 World J Mens Health meta-analysis (PMID 39434392) directly addressed this in congenital hypogonadotropic hypogonadism (CHH). The headline result was that combination therapy (hCG + FSH) produced higher rates of sperm recovery and shorter induction times compared with hCG monotherapy, but hCG monotherapy was still effective in a substantial proportion of patients.
A 2024 Fertility and Sterility paper examining post-TRT restoration protocols used 3000 IU hCG plus 75 IU FSH three times per week as an intensive regimen, reporting strong recovery outcomes.
For TRT adjuvant use, the picture is different from CHH. In men on TRT who already had baseline fertility, hCG alone typically suffices to preserve ITT and maintain spermatogenesis, because FSH suppression is the downstream problem, not the starting point. When spermatogenesis fails to return despite adequate hCG, adding FSH is the standard next step. Walia's 2025 review in Trends in Urology & Men's Health presents this same layered approach for clinicians managing TRT candidates.
Practical Dosing Windows from the Literature
The research literature supports two main dosing contexts, which are often confused:
TRT adjuvant for fertility and volume preservation (prophylactic). The Coviello line of evidence and common clinical practice favour low-dose hCG, roughly 250 to 500 IU two or three times per week. This is sufficient to preserve ITT at a level compatible with ongoing spermatogenesis and testicular volume, without adding meaningfully to serum testosterone.
Induction or recovery of spermatogenesis (therapeutic). Shoaib 2025 and Muir 2025 support 1500 to 3000 IU two or three times per week when the goal is to re-establish sperm production from a suppressed baseline. Panken 2025 shows that pushing higher doses does not accelerate recovery, so the lower end of this range is generally reasonable.
These are research-literature ranges, not dosing advice. hCG is a prescription-only medication in the EU and the USA, and clinical use must be supervised by a qualified prescriber. Research use of hCG as a reagent is a different context entirely.
Quality Criteria for hCG
hCG is a glycoprotein, structurally far more complex than the small peptides that dominate the research-peptide market. This has implications for quality.
What to Look For
IU rather than mg: hCG is dosed in International Units reflecting bioactivity, because mass is a poor proxy for activity in a glycoprotein where glycosylation varies batch to batch. The vial label should state IU per vial clearly.
Lyophilised form: A proper hCG product is supplied as a lyophilised powder for reconstitution, preserved in a sealed vial. Pre-mixed solutions degrade much faster.
Independent testing: Janoshik Analytical analysis of identity and purity is the baseline for reputable suppliers. Certificates of Analysis should be available on request.
Storage
Lyophilised hCG is stable for months at -20 degC. After reconstitution with bacteriostatic water, keep refrigerated at 2-8 degC and use within approximately 30 days. Do not freeze reconstituted solution; freeze-thaw cycles damage the protein structure and reduce bioactivity.
Reconstitution
Lyophilised hCG is reconstituted with bacteriostatic water. The procedure is standard across peptides of this class.
USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
EU shipping: PeptidesDirect ships hCG from within the EU with full tracking. Delivery is typically two to three working days, without customs delays or import fees for EU recipients.
Order hCG for Research
Human chorionic gonadotropin as a research reagent, in lyophilised form, with independent batch analysis by Janoshik Analytical and EU shipping.
Reproductive hormone that mimics luteinizing hormone (LH) activity. Used in research on testosterone production, fertility, and hormonal regulation. Available in 6,000 IU and 15,000 IU vials.
For research use only. hCG is a prescription-only medication in the EU and the USA; research reagents are not intended for human consumption or therapeutic use. hCG is also listed on the WADA Prohibited List (S2 class) for male athletes in competitive contexts.